Concept Life Sciences appoints Matthew Jones as Chief Commercial Officer

Jones has two decades of experience in the life sciences industry

Concept Life Sciences, a newly formed international scientific laboratory and consultancy business, has appointed Matthew Jones as Chief Commercial Officer.

Jones will be responsible for leading Concepts’ global commercial organisation, which encompasses all sales, business development, marketing activities and strategic partnering efforts.

Prior to joining Concept, Jones was Executive Vice President at Human Care Systems; Vice President Global Head Sales & Business Development at Lonza Biologics; Vice President of Business Development & Marketing at Ricerca BioSciences; and Vice President of Business Development at MDS Pharma Services. He has also held senior level clinical leadership roles within the biopharmaceutical industry with Alkermes and GlaxoSmithKline.

You may also like

Regulatory

Concept Life Sciences expands integrated drug development services

FEI registration will enable release-testing of pharmaceutical raw materials and finished products for the US market
Research & Development

Concept Life Sciences Group acquired by Spectris

Concept Life Sciences, the integrated drug discovery, development and analytical services, and environmental consultancy company, announced the completion of its acquisition by Spectris, the productivity-enhancing instrumentation and controls company
Research & Development

Concept Life Sciences expands into Alderley Park to support discovery services growth

New state-of-the-art facilities increase scientific capacity by more than 30%
Research & Development

Concept Life Sciences acquires CXR Biosciences

To expand its service base in discovery and pre-clinical sciences
Research & Development

Concept Life Sciences creates a UK based $100m life sciences group

More acquisitions are planned in the near future
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now